Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age15-90
SponsorHospital Regional de Alta Especialidad del Bajio
About this trial
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade
1?
Eligibility criteria
Qualifiers
Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk.
Age ≥ 18 years and ≤ 90 years.
Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN
Disqualifiers
Voluntary withdrawal from the study.
Develop grade 3 or 4 toxicity according to the INH scale.
Loss of follow-up
Trial design
Treatments tested in this trial
- Brentuximab Vedotin 50 MG [Adcetris]
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Hospital Regional de Alta Especialidad del Bajio
Lead sponsor
Universidad de Guanajuato
Collaborator
Source ClinicalTrials.gov